Skip to content

Study · Measured the body's own peptide · 2019

4 results

Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.

Knoop A, Thomas A, Thevis M

Rapid communications in mass spectrometry : RCM1 Feb 2019Cited by 19 (Europe PMC)

PMID30394592 (opens in a new tab)DOI10.1002/rcm.8337 (opens in a new tab)PepBankPUB-30394592
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In 20 healthy subjects, ELISA measured the body's own plasma MOTS‑c at 45.9-218.5 ng/mL, but LC/MS could not confirm these levels.

    In plain wordsIn 20 healthy adults, an ELISA test found a wide range of natural MOTS‑c levels, which a second method could not confirm.

    Peptide
    MOTS-c
    Outcome
    Not applicableEndogenous plasma MOTS-c by ELISA
    Study

    n = 20

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Endogenous MOTS-c by ELISA
    45.9 to 218.5 ng/mL
    20 healthy subjects

    Source sentences

    Summary
    However, endogenous levels of a reference population of 20 healthy subjects studied by ELISA experiments (45.9-218.5 ng/mL) could not be confirmed by LC/MS.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone3

In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MOTS-c.

  1. 02LabNot a test of MOTS-c aloneIn vitro (cell-free)Other

    An LC/MS method for MOTS‑c in plasma was fully validated according to WADA's International Standard for Laboratories.

    In plain wordsA lab test that detects MOTS‑c in blood plasma met anti-doping validation standards.

    Peptide
    MOTS-c
    Outcome
    Not applicableLC/MS assay validation for MOTS-c in plasma
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The LC/MS-based test method was fully validated for quantitative results interpretation according to the World Anti-Doping Agency's International Standard for Laboratories (WADA's ISL).

    In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.

  2. 03LabNot a test of MOTS-c aloneIn vitro (cell-free)Other

    The LC/MS assay detected human MOTS‑c in plasma down to a lower limit of detection of 100 pg/mL.

    In plain wordsThe lab test could detect MOTS‑c in plasma down to 100 pg/mL.

    Peptide
    MOTS-c
    Outcome
    Not applicableLower limit of detection of the LC/MS assay
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    LLOD
    100 pg/mL
    hMOTS-c in plasma

    Source sentences

    Summary
    It was found to be specific and sensitive, enabling a lower limit of detection (LLOD) for hMOTS-c in plasma at 100 pg/mL.

    In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.

  3. 04LabNot a test of MOTS-c aloneIn vitro (cell-free)Other

    Measured MOTS‑c levels differed considerably between the LC/MS assay and a commercial ELISA.

    In plain wordsTwo ways of measuring MOTS‑c gave quite different results.

    Peptide
    MOTS-c
    Outcome
    Not applicableAgreement between LC/MS and ELISA for MOTS-c
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The analytical approach was compared with a commercially available ELISA, and considerable differences in measured MOTS-c levels were observed.

    In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.